180 related articles for article (PubMed ID: 7572582)
1. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
3. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
[TBL] [Abstract][Full Text] [Related]
4. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
[TBL] [Abstract][Full Text] [Related]
5. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
[TBL] [Abstract][Full Text] [Related]
6. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
[TBL] [Abstract][Full Text] [Related]
7. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
[TBL] [Abstract][Full Text] [Related]
8. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
9. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
Portegies MC; Schmitt R; Kraaij CJ; Braat SH; Gassner A; Hagemeijer F; Pozenel H; Prager G; Viersma JW; van der Wall EE
J Cardiovasc Pharmacol; 1991 Nov; 18(5):746-51. PubMed ID: 1723772
[TBL] [Abstract][Full Text] [Related]
10. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
[TBL] [Abstract][Full Text] [Related]
11. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
[TBL] [Abstract][Full Text] [Related]
12. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie BM
Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
[TBL] [Abstract][Full Text] [Related]
13. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
14. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
15. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Charlon V; Kobrin I
Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
[TBL] [Abstract][Full Text] [Related]
17. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Davies GJ; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
Alpert JS
Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
[No Abstract] [Full Text] [Related]
19. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
20. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN; Markham A
Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]